SavedAdd your journal

Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2015 / Cilt: 49 - Sayı: 4

The importance of prediabetes and therapeutic approach

Prediyabetin Önemi ve Tedavi Yaklaşımı

YÜKSEL ALTUNTAŞ
Feyza ÖZTÜRK YENER
Pages
238–242
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

So, early diagnosis and treatment for prediabetes may interfere in preventing type 2 diabetes development.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prediabetes is the intermediate period between normoglycemia and type 2 diabetes mellitus.
📊
Key Findings & Data:Fasting plasma glucose concentration between 100 and 125 mg/dl (Impaired fasting glucose) or second hour plasma glucose concentration of oral glucose tolerance test between 140-199 mg/dl (Impaired glu- cose tolerance) is termed as prediabetes.
💡
Conclusion & Impact:So, early diagnosis and treatment for prediabetes may interfere in preventing type 2 diabetes development.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Prediabetes is the intermediate period between normoglycemia and type 2 diabetes mellitus. Fasting plasma glucose concentration between 100 and 125 mg/dl (Impaired fasting glucose) or second hour plasma glucose concentration of oral glucose tolerance test between 140-199 mg/dl (Impaired glu- cose tolerance) is termed as prediabetes. Also, HbA1c level between 5.7-6.4% has been accepted as prediabetes according to the recommendations of ADA in 2010. Every year 5 to 10% of prediabetic patients progress into type 2 diabetes mellitus. As associated with dislipidemia, hypertension and obesity, prediabetes is an important risk factor for developing cardiovascular diseases. So, early diagnosis and treatment for prediabetes may interfere in preventing type 2 diabetes development.

Özet

Prediyabet, tip 2 diyabet ve normoglisemi arasındaki ara dönem olarak tanımlanabilir. Açlık plazma glukozunun 100-125 mg/dl olması (Bozulmuş açlık glukozu) ya da 75 gr oral glukoz tolerans testinde 2 saat plazma glukozunun 140-199 mg/dl olması (Bozulmuş glukoz toleransı) prediyabet olarak adlandırılır. ADA 2010 önerilerine göre HbA1c düzeyinin %5.7–6.4 arasında olması da prediyabet kabul edilmiştir. Prediyabetiklerin her yıl %5-10u aşikar tip 2 diyabete dönüşmektedir. Dislipidemi, hipertansiyon ve obezite ile ilişkili olan prediyabet, kardiyovasküler hastalık açısından ciddi risk faktörüdür. Bu nedenle, prediyabetin erken tanınması ve tedavisi ile tip 2 diyabet gelişimine müdahale edilebilir.

🔖

Cite This Article

ALTUNTAŞ, Y., YENER, F. Ö. (2015). The importance of prediabetes and therapeutic approach. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 49 - Sayı: 4, 238–242. https://ajindex.com/articles/364048

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379: 2279-90
  2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97
  3. Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305-12
  4. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19:708-23
  5. Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I. Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev 2007; 23: 551-8
  6. Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 1999; 22: 399-402
  7. Gabir MM, Hanson R, Dabelea D, Imperatore G, Roumain J, Bennett PH, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000; 23: 1113-8. 8. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care 1998; 21: 1686-90
  8. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800-11
  9. Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, et al. A1C level and future risk of diabetes: A systematic review. Diabetes Care 2010; 33: 1665-73
  10. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2010; 33(Suppl1): S11-S61
  11. Abdul-Ghani MA, Adbul-Ghani T, Ali N, Defronzo RA. One- hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 2008; 31: 1650-5
  12. Fiorentino TV, Marini MA, Andreozzi F, A